Astrazeneca PLC (AZN) Receives “Hold” Rating from Shore Capital
Astrazeneca PLC (NYSE:AZN)‘s stock had its “hold” rating reiterated by research analysts at Shore Capital in a report issued on Saturday.
A number of other equities analysts have also weighed in on the company. Bank of America Corp. set a $41.00 price objective on Astrazeneca PLC and gave the stock a “buy” rating in a research note on Tuesday. Goldman Sachs Group Inc. reaffirmed a “sell” rating on shares of Astrazeneca PLC in a report on Wednesday. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Astrazeneca PLC in a report on Tuesday. Zacks Investment Research downgraded Astrazeneca PLC from a “hold” rating to a “sell” rating in a report on Tuesday. Finally, Deutsche Bank AG reaffirmed a “buy” rating on shares of Astrazeneca PLC in a report on Wednesday, September 28th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $37.44.
Astrazeneca PLC (NYSE:AZN) opened at 32.29 on Friday. Astrazeneca PLC has a 52 week low of $26.97 and a 52 week high of $35.04. The company’s 50-day moving average price is $33.23 and its 200 day moving average price is $30.79. The company has a market capitalization of $81.69 billion, a PE ratio of 36.90 and a beta of 0.75.
Astrazeneca PLC (NYSE:AZN) last issued its quarterly earnings results on Thursday, July 28th. The company reported $0.83 EPS for the quarter, beating the consensus estimate of $0.76 by $0.07. Astrazeneca PLC had a return on equity of 28.02% and a net margin of 9.23%. The firm earned $5.60 billion during the quarter, compared to analysts’ expectations of $5.56 billion. The business’s quarterly revenue was down 4.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.21 earnings per share. On average, equities research analysts anticipate that Astrazeneca PLC will post $2.97 EPS for the current year.
The business also recently declared a dividend, which was paid on Monday, September 12th. Shareholders of record on Friday, August 12th were paid a dividend of $0.44 per share. The ex-dividend date was Wednesday, August 10th. Astrazeneca PLC’s dividend payout ratio (DPR) is currently 78.29%.
Several institutional investors have recently made changes to their positions in the company. Forester Capital Management LTD increased its position in Astrazeneca PLC by 68.4% in the first quarter. Forester Capital Management LTD now owns 3,200 shares of the company’s stock valued at $109,000 after buying an additional 1,300 shares during the last quarter. First Interstate Bank boosted its stake in shares of Astrazeneca PLC by 233.3% in the second quarter. First Interstate Bank now owns 3,900 shares of the company’s stock worth $118,000 after buying an additional 2,730 shares during the last quarter. Synovus Financial Corp boosted its stake in shares of Astrazeneca PLC by 29.7% in the second quarter. Synovus Financial Corp now owns 4,372 shares of the company’s stock worth $132,000 after buying an additional 1,000 shares during the last quarter. Fifth Third Bancorp boosted its stake in shares of Astrazeneca PLC by 2.3% in the second quarter. Fifth Third Bancorp now owns 4,631 shares of the company’s stock worth $140,000 after buying an additional 103 shares during the last quarter. Finally, Integrated Investment Consultants LLC boosted its stake in shares of Astrazeneca PLC by 6.1% in the second quarter. Integrated Investment Consultants LLC now owns 4,756 shares of the company’s stock worth $144,000 after buying an additional 275 shares during the last quarter. Hedge funds and other institutional investors own 11.39% of the company’s stock.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.